Kendall Law Group Investigates Trubion Pharmaceuticals, Inc. Acquisition for Shareholders
13 Août 2010 - 10:14PM
Business Wire
Kendall Law Group, led by a former federal judge with attorneys
that include a former U.S. Attorney, is investigating Trubion
Pharmaceuticals, Inc. (NASDAQ: TRBN) for shareholders in connection
with the proposed acquisition by Emergent BioSolutions Inc. The
national securities firm’s investigation seeks to determine whether
Trubion and its Board breached their fiduciary duties by entering
into the agreement without properly shopping for a deal that would
provide better value for shareholders. If you are a Trubion
shareholder and would like additional information about your
rights, contact the Kendall Law Group at 877-744-3728 or by email
at skendall@kendalllawgroup.com.
On August 12, 2010, Trubion announced that it had entered into a
definitive merger agreement with Emergent BioSolutions Inc., in
which Emergent has agreed to acquire Trubion. Under the terms of
the agreement, each share of Trubion common stock will be converted
into the right to receive an upfront payment of $1.365 per share in
cash and 0.1641 shares of Emergent stock, reported by the company
as a value of $4.55 per share at the time of its announcement.
Trubian closing share prices have reached as high as $4.50 in late
April of this year. In addition, according to Thompson/First Call,
at least one analyst has set a price target of $7.00 per share.
Kendall Law Group was founded by former federal judge Joe
Kendall, includes a former United States Attorney, prosecutors and
securities lawyers who are experienced in complex securities
litigation. The firm has been counsel in numerous merger and
acquisition cases nationwide, including some of the largest
transactions in the United States.
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Trubion Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Kendall Law Group